Gilead Sciences, Inc. (GILD) Given Consensus Recommendation of “Buy” by Analysts

Share on StockTwits

Shares of Gilead Sciences, Inc. (NASDAQ:GILD) have earned a consensus recommendation of “Buy” from the twenty-three brokerages that are presently covering the company, Marketbeat Ratings reports. Nine equities research analysts have rated the stock with a hold recommendation and fourteen have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $82.35.

Several equities analysts recently weighed in on the stock. Mizuho set a $88.00 target price on shares of Gilead Sciences and gave the company a “buy” rating in a report on Friday, May 10th. JPMorgan Chase & Co. restated a “buy” rating and set a $87.00 target price on shares of Gilead Sciences in a report on Tuesday, May 7th. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a report on Monday, May 6th. Raymond James set a $83.00 target price on shares of Gilead Sciences and gave the company a “buy” rating in a report on Friday, May 3rd. Finally, Cowen reiterated a “buy” rating on shares of Gilead Sciences in a report on Friday, May 3rd.

In related news, Director Richard James Whitley sold 9,534 shares of the business’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $65.48, for a total transaction of $624,286.32. Following the completion of the sale, the director now owns 34,669 shares of the company’s stock, valued at approximately $2,270,126.12. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Gayle E. Wilson sold 19,068 shares of the business’s stock in a transaction dated Tuesday, February 19th. The shares were sold at an average price of $67.08, for a total transaction of $1,279,081.44. Following the sale, the director now directly owns 143,567 shares of the company’s stock, valued at approximately $9,630,474.36. The disclosure for this sale can be found here. In the last 90 days, insiders sold 47,670 shares of company stock worth $3,142,526. Company insiders own 0.20% of the company’s stock.

Several large investors have recently made changes to their positions in the stock. Athena Capital Advisors LLC bought a new position in Gilead Sciences in the 4th quarter worth about $27,000. Capital Financial Planning LLC bought a new position in Gilead Sciences in the 4th quarter worth about $27,000. Creative Financial Designs Inc. ADV grew its position in Gilead Sciences by 55.9% in the 1st quarter. Creative Financial Designs Inc. ADV now owns 460 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 165 shares during the last quarter. Advisors Preferred LLC bought a new position in Gilead Sciences in the 4th quarter worth about $31,000. Finally, Legacy Financial Advisors Inc. grew its position in Gilead Sciences by 361.3% in the 4th quarter. Legacy Financial Advisors Inc. now owns 489 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 383 shares during the last quarter. 79.94% of the stock is owned by institutional investors and hedge funds.

Shares of NASDAQ:GILD traded up $0.86 during midday trading on Thursday, hitting $66.16. 65,775 shares of the company’s stock traded hands, compared to its average volume of 7,339,546. The company has a current ratio of 3.62, a quick ratio of 3.53 and a debt-to-equity ratio of 1.09. The firm has a market capitalization of $81.81 billion, a price-to-earnings ratio of 10.75, a PEG ratio of 0.78 and a beta of 1.14. Gilead Sciences has a twelve month low of $60.32 and a twelve month high of $79.61.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $1.76 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.53 by $0.23. The business had revenue of $5.28 billion for the quarter, compared to analyst estimates of $5.29 billion. Gilead Sciences had a net margin of 26.40% and a return on equity of 37.98%. The business’s quarterly revenue was up 3.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.48 EPS. On average, analysts predict that Gilead Sciences will post 6.6 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 27th. Stockholders of record on Friday, June 14th will be paid a $0.63 dividend. The ex-dividend date is Thursday, June 13th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.81%. Gilead Sciences’s dividend payout ratio (DPR) is presently 40.98%.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

See Also: Discount Rate

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Kimball Electronics  Stock Rating Upgraded by BidaskClub
Kimball Electronics Stock Rating Upgraded by BidaskClub
Peel Hunt Increases Hotel Chocolat Group  Price Target to GBX 365
Peel Hunt Increases Hotel Chocolat Group Price Target to GBX 365
Analyzing PAC BASIN SHIPP/ADR  & Scorpio Bulkers
Analyzing PAC BASIN SHIPP/ADR & Scorpio Bulkers
Lovesac Co  Given Consensus Rating of “Strong Buy” by Brokerages
Lovesac Co Given Consensus Rating of “Strong Buy” by Brokerages
Atara Biotherapeutics  Now Covered by Stifel Nicolaus
Atara Biotherapeutics Now Covered by Stifel Nicolaus
Critical Contrast: MFC Bancorp  and Bancolombia
Critical Contrast: MFC Bancorp and Bancolombia


© 2006-2019 Ticker Report